GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells

BACKGROUND: Docetaxel is the first chemotherapy agent approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). The limited survival benefit associated with the quick emergence of resistance and systemic toxicity diminished its efficacy. JNK-mediated apoptosis is one of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Karanika, Styliani, Karantanos, Theodoros, Kurosaka, Shinji, Wang, Jianxiang, Hirayama, Takahiro, Yang, Guang, Park, Sanghee, Golstov, Alexei A., Tanimoto, Ryuta, Li, Likun, Thompson, Timothy C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484888/
https://www.ncbi.nlm.nih.gov/pubmed/26084402
http://dx.doi.org/10.1186/s12943-015-0395-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484888/
https://www.ncbi.nlm.nih.gov/pubmed/26084402
http://dx.doi.org/10.1186/s12943-015-0395-0

Ejemplares similares